Pharmacy Times July 16, 2024
Data presented show significant advancements in treatment options.
The American Society of Clinical Oncology (ASCO) Annual Meeting was held May 31 to June 4, 2024, in Chicago, Illinois, featuring more than 200 sessions educating attendees on the latest information from oncology research. Below are some valuable highlights from these sessions for oncology pharmacy clinical practice.
Lung Cancer
Phase 3 CROWN Trial
Significant progression-free survival (PFS) advantage was demonstrated with lorlatinib (Lorbrena; Pfizer Inc) vs crizotinib (Xalkori; Pfizer Inc) in patients with previously untreated, advanced ALK-positive non–small cell lung cancer (NSCLC). The results from the phase 3 CROWN trial (NCT03052608) demonstrated a median PFS (mPFS) of not reached (NR) in the lorlatinib group vs 9.1 months in the crizotinib group. Time...
Today's Sponsors
Today's Sponsor